Jin Rong Jie·2025-08-12 08:51Core Viewpoint - The article discusses the performance of the Shanghai Composite Index and the Hang Seng Index, along with the premium of Fudan Zhangjiang's A-shares over H-shares, highlighting the company's position in the biopharmaceutical industry and its ongoing innovations in drug development [1][2]. Group 1: Market Performance - On August 12, the Shanghai Composite Index rose by 0.5%, closing at 3665.92 points, while the Hang Seng Index increased by 0.25%, closing at 24969.68 points [1]. - Fudan Zhangjiang's A-share premium reached 187.84%, ranking third among A/H shares [1]. Group 2: Company Overview - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1]. - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1]. - Fudan Zhangjiang has developed competitive advantages in various fields, including gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1]. - The company has undertaken several national key technology projects and major scientific initiatives, demonstrating its strength in the biopharmaceutical field [1].